-
Stifel Downgrades IGM Biosciences (IGMS) to Hold
-
BMO Capital Downgrades IGM Biosciences (IGMS) to Market Perform
-
BMO Capital Starts IGM Biosciences (IGMS) at Outperform
-
IGM Biosciences Inc. (IGMS) Misses Q3 EPS by 21c
-
IGM Biosciences (IGMS) PT Raised to $20 at RBC Capital
-
Stifel Reiterates Buy Rating on IGM Biosciences (IGMS)
-
Truist Securities Downgrades IGM Biosciences (IGMS) to Hold
-
IGM Biosciences (IGMS) PT Lowered to $17 at RBC Capital
-
Jefferies Reiterates Buy Rating on IGM Biosciences (IGMS)
-
Morgan Stanley Reiterates Equalweight Rating on IGM Biosciences (IGMS)
-
JPMorgan Downgrades IGM Biosciences (IGMS) to Underweight
-
After-hours movers: IGM Biosciences, Biohaven Pharma, Acadia Realty Trust
-
IGM Biosciences (IGMS) Announces Strategic Pivot to Focus Exclusively on Autoimmunity
-
IGM Biosciences Inc. (IGMS) Falls 27% After Announcing Plans to Prioritize its Pipeline of T Cell Engagers
-
IGM Biosciences (IGMS) PT Lowered to $11 at H.C. Wainwright
-
Morgan Stanley Reiterates Overweight Rating on IGM Biosciences (IGMS)
-
IGM Biosciences Inc. (IGMS) Misses Q2 EPS by 75c; offers guidance

